Brand dynamics

Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health

Latest progress revealed: The phase III clinical trial of the Lizhu COVID-19 vaccine V-01 sequential booster is undergoing interim data analysis.

Published Time:

2022-02-15

Recently, during an investor relations meeting, Lizhu Group announced that the overseas Phase III clinical trial of its recombinant protein COVID-19 vaccine, V-01, has completed subject enrollment and endpoint case collection in some countries. The Phase III clinical trial conducted in Pakistan and Malaysia as a third-dose sequential booster based on an inactivated vaccine has reached the interim analysis target set in the protocol, and the interim data analysis is currently underway. The Phase III clinical trial for basic immunization has also reached the interim analysis target set in the protocol, and data cleaning and preparation for interim analysis are actively underway.

 

It is understood that the COVID-19 vaccine V-01 is a recombinant protein vaccine jointly developed by Lizhu Bio and the Chinese Academy of Sciences. In addition to its many advantages, including low biosafety level requirements for production facilities, high purity, better safety, high yield, low cost, and rapid development of new vaccines targeting variants, V-01 also uses conventional aluminum adjuvant, with a stable and sufficient supply chain and a production capacity of 1.5 billion doses. Phase II clinical trial data for the V-01 vaccine was published in the Chinese Medical Journal in July 2021. The results showed that the vaccine has excellent immunogenicity and safety, especially with a lower overall incidence of vaccine-related adverse events in the elderly group compared to the adult group. The Phase III sequential booster clinical trial of V-01 was launched in Pakistan in October 2021. Based on current progress, this vaccine should be the first and fastest domestically developed vaccine to undergo a formal sequential immunization Phase III clinical trial overseas.

 

If the Phase III clinical trial of the V-01 vaccine yields positive results, it is expected to accelerate the market launch process and may be strongly promoted as a superior booster option.

 

(This article does not constitute any investment advice. Information disclosure is subject to the company's announcements. Investors operate at their own risk.)

 

Source: Daily Economic News